Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BioDrugs
Published in: BioDrugs 5/2016

01-10-2016 | Adis Drug Evaluation

Talimogene Laherparepvec: A Review in Unresectable Metastatic Melanoma

Author: Karly P. Garnock-Jones

Published in: BioDrugs | Issue 5/2016

Login to get access

Abstract

Talimogene laherparepvec (Imlygic™) is a first-in-class oncolytic viral immunotherapy derived from herpes simplex virus type 1, which has been genetically modified to increase tumour selectivity and stimulate antitumour immune response. This article reviews the pharmacological properties of intralesional talimogene laherparepvec and its clinical efficacy and tolerability in patients with unresectable metastatic melanoma. In the phase III OPTiM trial, talimogene laherparepvec was more effective than subcutaneous human granulocyte-macrophage colony-stimulating factor (GM-CSF), both in patients with stage IIIB–IV melanoma [intention-to-treat (ITT) population] and in those with stage IIIB–IVM1a disease (in an exploratory subgroup analysis). Durable response rate (DRR) was significantly higher with talimogene laherparepvec in the ITT population; beneficial results in DRR were also observed in talimogene laherparepvec recipients in patients with stage IIIB–IVM1a disease. Talimogene laherparepvec was generally well tolerated in clinical trials. In conclusion, talimogene laherparepvec is a novel, effective and well tolerated option for the treatment of patients with unresectable metastatic melanoma.
Literature
1.
Kaufman HL, Kirkwood JM, Hodi FS, et al. The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol. 2013;10(10):588–98.CrossRefPubMed
2.
Shah D, Dronca R. Latest advances in chemotherapeutic, targeted, and immune approaches in the treatment of metastatic melanoma. Mayo Clin Proc. 2014;89(4):504–19.CrossRefPubMedPubMedCentral
3.
Maverakis E, Cornelius LA, Bowen GM, et al. Metastatic melanoma—a review of current and future treatment options. Acta Derm Venereol. 2015;95(5):516–27.CrossRefPubMed
4.
Dummer R, Hauschild A, Lindenblatt N, et al. Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v126–32.CrossRefPubMed
5.
Zeyaullah M, Patro M, Ahmad I, et al. Oncolytic viruses in the treatment of cancer: a review of current strategies. Pathol Oncol Res. 2012;18(4):771–81.CrossRefPubMed
6.
Dharmadhikari N, Mehnert JM, Kaufman HL. Oncolytic virus immunotherapy for melanoma. Curr Treat Options Oncol. 2015;16(3):326.CrossRefPubMed
7.
Harrington KJ, Puzanov I, Hecht JR, et al. Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy. Expert Rev Anticancer Ther. 2015;15(12):1389–403.CrossRefPubMed
8.
9.
Amgen Inc. Imlygic™ (talimogene laherparepvec) suspension for intralesional injection: US prescribing information. 2015. http://​www.​fda.​gov. Accessed 1 Aug 2016.
10.
Liu BL, Robinson M, Han ZQ, et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther. 2003;10(4):292–303.CrossRefPubMed
11.
Kohlhapp FJ, Kaufman HL. Molecular pathways: mechanism of action for talimogene laherparepvec, a new oncolytic virus immunotherapy. Clin Cancer Res. 2015;22(5):1048–54.CrossRefPubMed
12.
Cooke K, Rottman J, Zhan J, et al. OncoVEXmGM-CSF-mediated regression of contralateral (non-injected) tumors in the A20 murine lymphoma model does not involve direct viral oncolysis. J Immunother Cancer. 2015;3(Suppl 2):336.CrossRef
13.
Piasecki J, Rottman J, Le T, et al. Talimogene laherparepvec activates systemic T-cell-mediated anti-tumor immunity [abstract no. 4287]. Cancer Res. 2015;75(15 Suppl).
14.
Cooke K, Fitzgerald K, Yang B, et al. Innate and adaptive immunity contribute to the anti-tumor mechanisms of action of OncoVEXmGM-CSF. J Immunother Cancer. 2015;3(Suppl 2):338.CrossRef
15.
Hu JCC, Coffin RS, Davis CJ, et al. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res. 2006;12(22):6737–47.CrossRefPubMed
16.
Kaufman HL, Kim DW, Deraffele G, et al. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol. 2010;17(3):718–30.CrossRefPubMed
17.
Fu Y, De Moll EH, Beers C, et al. Treatment of melanoma using talimogene laherparepvec and vemurafenib combination therapy in murine model [abstract no. 226]. J Invest Dermatol. 2014;134(Suppl 1):S39.
18.
Piasecki J, Le T, Ponce R, et al. Talilmogene laherparepvec increases the anti-tumor efficacy of the anti-PD-1 immune checkpoint blockade [abstract no. 258]. Cancer Res. 2015;75(15 Suppl).
19.
Puzanov I, Milhem M, Andtbacka RHI, et al. Survival, safety, and response patterns in a phase 1b multicenter trial of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma [abstract no. 9063]. J Clin Oncol. 2015;33(Suppl).
20.
Long GV, Dummer R, Ribas A, et al. Primary analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma [abstract]. In: Society for Melanoma Research (SMR) congress. 2015.
21.
Senzer NN, Kaufman HL, Amatruda T, et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol. 2009;27(34):5763–71.CrossRefPubMed
22.
Andtbacka RHI, Kaufman HL, Collichio F, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33(25):2780–8.CrossRefPubMed
23.
Harrington KJ, Andtbacka RH, Collichio F, et al. Disease characteristics, treatment outcomes and safety with talimogene laherparepvec vs GM-CSF in patients with stage IIIB/C and IVM1a melanoma in OPTiM [abstract no. P006 plus poster]. In: 11th EADO Congress and 8th World meeting of Interdisciplinary Melanoma/Skin Centers. 2015.
24.
Andtbacka RHI, Collichio FA, Amatruda T, et al. Final planned overall survival (OS) from OPTiM, a randomized phase III trial of talimogene laherparepvec (T-VEC) versus GM-CSF for the treatment of unresected stage IIIB/C/IV melanoma (NCT00769704) [abstract no. P263]. J Immunother Cancer. 2014;2(Suppl 3).
25.
Andtbacka RHI, Kaufman H, Collichio F, et al. Reduced risk of developing visceral/bone metastasis (VM) in patients (pts) with stage IIIB/C/IVM1a melanoma treated with talimogene laherparepvec (T-VEC) vs GM-CSF [abstract no. Pigment Cell Melanoma Res. 2015;28(6):753–4.CrossRef
26.
Nemunaitis JJ, Andtbacka RHI, Ross M, et al. Results of the extension trial of OPTiM, a multicenter, randomized phase 3 trial of talimogene laherparepvec (T-VEC) vs GM-CSF for unresected stage IIIb-IV melanoma [abstract no. 1102P]. Ann Oncol. 2014;25(Suppl 4):iv382.
Metadata
Title
Talimogene Laherparepvec: A Review in Unresectable Metastatic Melanoma
Author
Karly P. Garnock-Jones
Publication date
01-10-2016
Publisher
Springer International Publishing
Published in
BioDrugs / Issue 5/2016
Print ISSN: 1173-8804
Electronic ISSN: 1179-190X
DOI
https://doi.org/10.1007/s40259-016-0189-y

Other articles of this Issue 5/2016

BioDrugs 5/2016 Go to the issue

Original Research Article

Reduction of Isoagglutinin in Intravenous Immunoglobulin (IVIG) Using Blood Group A- and B-Specific Immunoaffinity Chromatography: Industry-Scale Assessment

Review Article

Advances in the Treatment of Non–small Cell Lung Cancer: Focus on Nivolumab, Pembrolizumab, and Atezolizumab

Adis Drug Evaluation

Infliximab Biosimilar (CT-P13; Infliximab-dyyb): A Review in Autoimmune Inflammatory Diseases

Review Article

Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid Arthritis

Adis Drug Evaluation

BAY 81-8973 (Octocog Alfa; Kovaltry®): A Review in Haemophilia A

Erratum

Erratum to: Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid Arthritis